Eflornithine for Bone Cancer

This trial aims to determine whether adding eflornithine (DFMO) to standard treatments can improve outcomes for individuals with certain types of bone cancer, such as Ewing sarcoma and osteosarcoma. Researchers seek to assess if eflornithine can extend the time patients live without disease progression. The trial includes five groups, each targeting different stages or responses to these cancers. It is suitable for individuals with specific conditions, such as relapsed Ewing sarcoma or osteosarcoma that recurs in the lungs after surgery. Participants should have previously undergone standard treatments and continue to face challenges with their cancer. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.

Participants currently receiving other investigational drugs or anticancer agents are not eligible for the trial. If you are taking such medications, you will need to stop them to participate.

Research shows that eflornithine (DFMO) is usually well-tolerated by patients. One study found that DFMO slowed the growth of Ewing sarcoma tumors in animals and increased their survival time. DFMO has also been used in other cancers like neuroblastoma, where it successfully prevented recurrence. This suggests it might have a similar effect in bone cancers like Ewing sarcoma and osteosarcoma.

Earlier studies used DFMO alongside standard treatments or as follow-up therapy. Patients generally tolerated it well, with manageable side effects. However, since this trial is in a mid-stage, some safety information is available, but more data is needed to confirm its safety in a larger group of patients.

Researchers are excited about Eflornithine (DFMO) for bone cancer, specifically Ewing sarcoma and osteosarcoma, because it offers a novel approach to treatment. Unlike traditional chemotherapy, DFMO targets polyamine synthesis, which is crucial for cancer cell growth and survival. This mechanism is different from standard treatments like doxorubicin and cisplatin, which primarily target DNA replication. Additionally, DFMO is being explored for long-term maintenance therapy, providing extended care beyond initial treatment phases, which could potentially improve overall outcomes for patients.

Research has shown that DFMO (eflornithine) may help treat Ewing sarcoma and osteosarcoma, serious bone cancers. Studies have found that DFMO can slow tumor growth, reduce cancer spread, and possibly improve survival rates. This trial tests DFMO in different cohorts:

- Cohort 1 involves participants with relapsed or refractory Ewing sarcoma eligible for local control, receiving DFMO as concurrent therapy and maintenance treatment.

- Cohort 2 includes Ewing sarcoma patients metastatic at diagnosis, receiving DFMO during consolidation treatment and as post-consolidation maintenance.

- Cohort 3 focuses on osteosarcoma patients with lung relapse after resection of lung metastases, with DFMO dosed twice daily.

- Cohorts 4A and 4B involve osteosarcoma patients with poor response to induction therapy or metastatic disease at diagnosis, respectively, receiving DFMO during post-surgery consolidation and as maintenance treatment.